Breast cancers that don’t contain receptors for estrogen, progesterone, or HER2/NEU — called “triple-negative breast cancers” (TNBC) — are very difficult to treat successfully. Researchers are seeking new therapeutic targets for TNBC.
Abraxane is a form of paclitaxel that is commonly used to treat breast cancer. In this study, researchers are evaluating the safety and effectiveness of combining Abraxane with the investigational drug tigatuzumab in women with metastatic TNBC.
Tigatuzumab is an antibody that binds to a protein on TNBC cells called DR5 and causes cancer cell death. Laboratory studies have shown that tigatuzumab plus another chemotherapy agent, such as Abraxane, is more effective than either drug alone against breast cancer cells. In this study, patients will be randomly assigned to receive Abraxane with or without tigatuzumab.
A biopsy of each patient’s tumor may be required for research purposes.